Daklinza 60 mg Oral Tablet
RxNorm 1660196
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1660196 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Daklinza 60 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SY
Synonym (SY):
Daclatasvir 60 mg (as daclatasvir dihydrochloride 66 mg) Oral Tablet [Daklinza]
(Atom ID: 8230229)
SBD
Semantic Branded Drug (SBD):
Daclatasvir 60 mg Oral Tablet [Daklinza]
(Atom ID: 7256225)
PSN
Prescribable Name (PSN):
Daklinza 60 mg Oral Tablet
(Atom ID: 7256229)
SY
Synonym (SY):
Daklinza 60 mg Oral Tablet
(Atom ID: 7256226)
Patient Education
Daclatasvir
Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body. It is not known if daclatasvir prevents the spread of hepatitis C to other people.
[Learn More]
* Please review the disclaimer below.